Blueprint Medicines — Q1 2025 Earnings Presentation
14 slides from Blueprint Medicines's earnings presentation, May 1, 2025
Slide 1: Blueprint Medicines
Blueprint Medicines Driving growth and innovation with operational excellence First quarter 2025 financial and operating results May 1, 2025
Slide 2: First quarter 2025 financial and operating results
First quarter 2025 financial and operating results AYVAKIT CLINICAL FINANCIAL INTRODUCTION PERFORMANCE PROGRESS RESULTS Kate Haviland Philina Lee, PhD Becker Hewes, MD Mike Landsittel Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding its plans, strategies, timelines and expectations for the company’s operations,
Slide 4: Blueprint Medicines Q1 2025 highlights
Blueprint Medicines Q1 2025 highlights Growing Advancing Maintaining Revenue Our Pipeline Financial Strength Achieved $149.4 M in AYVAKIT revenue, Addressing numerous mast cell-driven diseases Durable and growing commercial revenue representing 61% YoY growth that leverage expertise and infrastructu
Slide 5: AYVAKIT commercial performance highlights
AYVAKIT commercial performance highlights AYVA K IT R EVEN U E G R O WT H • Continued growth in patients on therapy globally $, MILLIONS • Trend toward multi-year duration of therapy in SM 61% • Retained free goods favorability $149.4 • ~75% of SM patients started at 25 mg $20.0 $92.5 $9.4 $129.4 Ra
Slide 6: SM market is primed for long-term growth in AYVAKIT treatment
SM market is primed for long-term growth in AYVAKIT treatment AYVAKIT is the only approved disease-modifying therapy to treat the broad spectrum of SM A consistent safety and efficacy profile out to three-plus years A growing rare disease market, with ~60K SM patients in U.S.1 and ~25K diagnosed2 Si
Slide 7: Driving breadth and depth with significant headroom for continued growth
Driving breadth and depth with significant headroom for continued growth 7 Blueprint Medicines data on file. Cumulative SM AYVAKIT prescribers since ISM approval in May 2023. SM new patient starts since ISM launch are included. Data based upon SP/HUB prescriptions which represent ~70% of total AYVAK
Slide 8: Positive HCP perceptions of AYVAKIT that increase with time on market
Positive HCP perceptions of AYVAKIT that increase with time on market Proportion of Specialists Who View AYVAKIT’s Profile As Favorable 96% ~70% 90% 80% 82% 80% 77% Jun-24 Feb-25 of specialists managing ≥ 3 SM patients are allergy, derm, or GI Hematologists / Allergists / Dermatologists Gastroentero
Slide 9: Engaged patient base with growing interest and high satisfaction with AYVAKIT
Engaged patient base with growing interest and high satisfaction with AYVAKIT HCP-Reported Proportion of ISM Patients Asking for AYVAKIT >95% 42% 25% percent of AYVAKIT patients who strongly agree that they are satisfied with AYVAKIT as a treatment for their SM Jun-24 Feb-25 9 Blueprint Medicines ma
Slide 10: Consistent long-term AYVAKIT safety supporting chronic treatment
Consistent long-term AYVAKIT safety supporting chronic treatment Randomized controlled part 2a Open-label extension part 3b Avapritinib 25 mg Avapritinib 25 mg Placebo + BSC Avapritinib 50 mg 3 year follow up + BSC (n=141) (n=71) (N=57) (N=226) Median length of follow-up (months)c 5.5 5.5 35.3 10.6
Slide 11: AYVAKIT delivers durable efficacy through three years
AYVAKIT delivers durable efficacy through three years Total Symptom Score (TSS) Quality of Life (MC-QoL) (Mean change from baseline) (Mean % change from baseline) 0 0 • Durable improvements in -2 AYVAKIT 25 mg AYVAKIT 25 mg AYVAKIT 25 mg AYVAKIT 25 mg TSS and all individual Week 96 Week 144 -5 Week
Slide 12: First two BLU-808 proof of concept studies initiated
First two BLU-808 proof of concept studies initiated BLU-808 PROOF-OF-CONCEPT STRATEGY UNIVERSE OF ALLERGIC & INFLAMMATORY DISEASES Move rapidly into areas where targeting KIT has been de-risked Respiratory Skin • Allergic asthma • Chronic urticaria Chronic spontaneous urticaria and • Allergic • P
Slide 13: A strong balance sheet driven by AYVAKIT revenue growth
A strong balance sheet driven by AYVAKIT revenue growth Three Monds Ended Three Months Ended Statement of Operations (unaudited) 3/31/2025 3/31/2024 Total revenue $149.4M $96.1M Net product sales $149.4M $92.5M Collaboration, license and other revenue - $3.6M Cost of sales $2.8M $3.2M Research & dev
Slide 14: Blueprint Medicines
Blueprint Medicines Driving growth and innovation with operational excellence